Protalex is a biotechnology company developing a new class of drugs with the potential to revolutionize the treatment of autoimmune diseases.
Immune Thrombocytopenia (ITP), is a blood disorder that can result in easy or excessive bleeding and bruising due to the body’s inability to form blood clots.
ITP occurs when the body’s own immune system attacks the platelets in the blood, rendering them ineffective. Platelets are created within the bone marrow and are responsible for creating blood clots to seal up cuts and stop bleeding.
Per 100,000 adults/year are diagnosed with ITP*
The amount of women who are affected by ITP compared to men*
*Sources: Platelet Disorder Support Association and National Institutes of Health
There are two types of Immune Thrombocytopenia (ITP): acute and chronic.
Immune Thrombocytopenia (ITP) is referred to as idiopathic, meaning “of unknown cause,” however some cases have been associated with viral or bacterial infections such as hepatitis C or HIV.
Currently, treatment occurs when patients present with significant bleeding. They can be prescribed a range of drugs that include glucocorticoids, intravenous immunoglobulin, and thrombopoeitic agents. The leading thrombopoetic agents are NPlate ® and Promacta ® with 2014 worldwide sales (across all indications) of $469 million and $340 million respectively. These treatments, however, are not curative and patients have high levels of relapse as none of the current treatments address the underlying cause of the disease- the destruction of the platelets.
PRTX-100 works through a different mechanism of action and attempts to limit the destruction of the platelets as opposed to the thrombopoetic agents that merely replace what has been lost. As such, there is a potential to markedly slow the disease as either a monotherapy or in combination with current standard of care.